MRI Scan and Intra-labyrinthine Schwannoma

Schwannoma Clinical Trial

Official title:

INTEREST OF INTRAVENOUS INJECTION OF GADOLINIUM IN EXPLORATION INTRA-LABYRINTHINE SCHWANNOMA IN MRI 3 TESLAS

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03580850
• Other study ID #: 6809
• Status: Recruiting
• Start date: February 2, 2018
• Est. completion date: February 2019

Study information

• Verified date: February 2018
• Source: University Hospital, Strasbourg, France
• Contact: Francis VEILLON, MD, PhD
• Phone: 33 3 88 12 78 65
• Email: Francis.veillon[@]chru-strasbourg.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Evaluate the interest of gadolinium for the positive and topographic diagnosis of intra-labyrinthine schwannoma, comparing T1 sequence acquired after gadolinium injection to a sequence of fast imaging type employing steady state acquisition (FIESTA-C)

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: February 2019
• Est. primary completion date: February 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Age 18-80 years

• Have intra-labyrinthine schwannoma

• Have benefited from an MRI with gadolinium injection on the MRI 3T with interpretable sequences of good quality

• Subject giving their consent for their participation

• Subjects who benefited, between 2009 and 2016, from an MRI of the external auditory canals, with gadolinous product injection and on the 3 Tesla MRI, in which a diagnosis of intra labyrinthine schwannoma was made

Exclusion Criteria:

• Refusal to participate in the study

Related Conditions & MeSH terms

• Neurilemmoma
• Schwannoma

Intervention

Other:
• No intervention in this restrospective study
This study is an obervational study

Locations

Country	Name	City	State
France	Service Imagerie 1	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Presence or absence of intra labyrinthine vestibular nerve tumor using T2 FIESTA alone		1 hour after the realization of the MRI